Navigation Links
Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
Date:8/14/2008

n blood pressure and increase in cGMP levels, diuresis (kidney excretion of water) and natriuresis (kidney excretion of sodium). The data from this first study has been accepted for presentation at the 12th Annual Scientific Meeting of the Heart Failure Society of America to be held in Toronto, Canada on September 21-24, 2008.

About Heart Failure (HF)

Currently in the U.S., HF affects nearly 5 million people with 550,000 new cases of HF diagnosed each year. Despite the treatment of HF with multiple drugs, almost all HF patients will experience at least one episode of acute HF that requires treatment with intravenous medications in the hospital. There were over 1.1 million hospitalizations for HF in 2004. Heart failure has tremendous human and financial costs. Estimated direct costs in the U.S. for HF were $29.6 billion in 2006.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of proprietary peptide, peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia and reperfusion injury, hemorrhagic shock and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of heart failure, hypertension and other cardiovascular diseases. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. The Company currently has collaborations with AstraZeneca and the Mallinckrodt division of Covidien. For additional information regarding P
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Nashville Fertility Center announced that ... for the American Society for Reproductive Medicine (ASRM), a ... in reproductive medicine. In his new role as ... executive board and will have a voice in furthering ... actively supported ASRM since 1984 when he joined while ...
(Date:12/24/2014)... December 23, 2014 PharmaBoardroom,s ... out today and available for free download , digs ... change and growth in the sector today. One ... successes has been in developing a homegrown pharmaceutical manufacturing base, ... production still remains some way off. A cursory comparison with ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Favrille, Inc. (OTC,Bulletin Board: FVRL) announced today that ... reverse merger whereby Favrille would acquire,all of the capital ... stock for stock merger that would result in MMR ... is,consummated on the terms set forth in the non-binding ...
... October, 2008, Stenum Hospital, Germany, just five years after Jim Rider, ... has now surpassed the 600 American patient milestone. , ... ... healthcare crisis in the US getting worse, and the knowledge that ...
... EST, HOPKINTON, Mass., Oct. 23 Caliper ... a conference call discussing the,company,s third quarter 2008 ... 10. Kevin Hrusovsky, President and Chief Executive Officer ... call. Management will,discuss operational and financial results and ...
Cached Biology Technology:Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction 2Stenum Hospital Does its 600th American Disc Replacement Surgery 2Caliper Life Sciences' Third Quarter 2008 Financial Results Conference Call Notice 2
(Date:12/3/2014)... -- As part of our commitment to offering the ... announce the release of a new reader that will ... data that they need. The Atlas 2000 ... readers. Many such devices have serious shortcomings when it ... models force users to navigate numerous complicated steps in ...
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
(Date:11/18/2014)... 2014  The Secure Identity & Biometrics Association ... announce the formation of The Airport Entry and ... Identity and Biometric Entry and Exit Solutions Framework ... support from BORDERPOL, the international non-profit organization that ... expertise regarding border security, traveler and migration systems. ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... present its fifth annual Regional Policy Award to Ken ... Society,s upcoming conference in Portland, Oregon. The ESA award ... an outstanding record of informing political decision-making with ecological ... prestigious award to Ken Bierly for his long-term commitment ...
... in German . Excitation of neurons ... calcium and potassium through specific channels. Obviously, these channels were ... such channels could have evolved their selectivity has been a ... University of Vienna together with Scientists from Tel Aviv University ...
... older adults especially those who are frail low levels ... The randomized, nationally representative study found that older adults with ... death than people who had higher levels. Overall, people ... than those who were not frail. Frail adults with low levels ...
Cached Biology News:Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award 2Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award 3Ion selectivity in neuronal signaling channels evolved twice in animals 2Lower vitamin D could increase risk of dying, especially for frail, older adults 2
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Lysozyme C (W-20)...
... The Jouan B4i ventilated and BR4i refrigerated ... and low speed operation at a low sound ... accessories certified for biocontainment. Their AUTO-LOCK rotor exchange ... is ready for use within seconds. ...
... is a chromogenic substrate ... plasmids. In the presence ... lac + bacterial ... recombinant colonies appear white. ...
Biology Products: